The Silicon Review

FDA Approves Vera's Trutakna: First Dual-Target IgAN Therapy Sets Up Market Showdown with Novartis and Otsuka

FDA grants accelerated approval to Vera's Trutakna for IgA nephropathy, first dual BAFF/APRIL inhibitor. Competes with ...